ArticleCellular oncology (Dordrecht, Netherlands)2026
Distinct clinical and genomic profiles of braf mutation subtypes in Chinese colorectal cancer: a retrospective cohort study with cross-population validation.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mutations of Kinases and GTPases in Cancers.Cancers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeTo characterize the clinicogenomic features, prognostic significance and therapeutic implications of BRAF mutation subtypes in Chinese colorectal cancer (CRC) patients.
methodsWe performed integrated genomic and clinical analyses on 146 BRAF-mutant colorectal cancers identified within a cohort of 2,446 consecutive CRC patients at Fudan University Shanghai Cancer Center (FUSCC) encompassing surgical, neoadjuvant, and advanced disease. Targeted sequencing defined genomic profiles, benchmarking against the western cohorts (TCGA/MSKCC). Clinical outcomes including overall survival (OS), metastasis site, and treatment response were assessed. Isogenic cell line models validated functional impacts of BRAF variants.
resultsThe FUSCC cohort exhibited a lower overall frequency of BRAF mutations, with V600E accounting for 54.1% of BRAF mutant cases. Compared with the western cohorts, Chinese patients harboring BRAF mutations were younger at diagnosis, presented with fewer metastatic cases, and displayed distinct co-mutation patterns, notably a higher prevalence of BRAFV600E-TP53 co-mutations which predicted poor prognosis. The BRAFV600E subtype was associated with significantly worse OS, an increased risk of peritoneal metastasis, female, advanced disease stage, and poor tumor differentiation compared with BRAFnon−V600E patients. In contrast, non-V600E tumors exhibited a higher tumor mutational burden. In vitro functional assays further confirmed that BRAFV600E mutant cells possessed enhanced proliferative and invasive capacities. Clinically, patients with BRAFV600E mutations demonstrated inferior responses to first-line therapy compared with non-V600E cases (ORR: 21.1% vs. 63.2%; P < 0.01), particularly in those receiving bevacizumab-based regimens.
conclusionBRAFV600E defines an aggressive CRC subset in Chinese patients with distinct genomic and clinical features, supporting the need for population-tailored precision oncology strategies in Asian populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.